Modern treatment of adult short bowel syndrome patients

Minerva Gastroenterologica e Dietologica

Volumn 57, Issue 4, 2011, Pages 405-417

  Efsen, E ^a   Jeppesen, P B ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Intestinal diseases; Short bowel syndrome; Therapeutics

Indexed keywords

CLONIDINE; CODEINE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 2; GLUTAMINE; GROWTH HORMONE; LOPERAMIDE; ORAL REHYDRATION SOLUTION; PLACEBO; TEDUGLUTIDE;

ADULT; CARBOHYDRATE DIET; DIARRHEA; DIET THERAPY; DRUG MEGADOSE; ENZYME DEGRADATION; HUMAN; INTESTINE ABSORPTION; INTESTINE FUNCTION; JEJUNOSTOMY; LOW FAT DIET; NONHUMAN; PARENTERAL NUTRITION; QUALITY OF LIFE; REVIEW; SHORT BOWEL SYNDROME;

ADULT; GLUCAGON-LIKE PEPTIDE 2; GROWTH HORMONE; HUMANS; SHORT BOWEL SYNDROME;

EID: 84856545900     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Messing B, Pigot F, Rongier M, Morin MC, Ndeïndoum U, Rambaud JC. Intestinal absorption of free oral hyperalimentation in the very short bowel syndrome. Gastroenterology 1991;100:1502-8.
2. Jeppesen PB, Mortensen PB. Intestinal failure defined by measurements of intestinal energy and wet weight absorption. Gut 2000;46:701-6. (Pubitemid 30305789)
3. Fleming CR, Remington M. Intestinal failure. In: Hill GL, editor. Nutrition and the Surgical Patient. New York: Churchill Livingstone, 1981. p. 219-35.
4. O'Keefe SJ, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol 2006;4:6-10. (Pubitemid 43129518)
5. Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 2003;124:1111-34. (Pubitemid 36389810)
6. Nightingale JM, Lennard Jones JE. The short bowel syndrome: what's new and old? Dig Dis 1993;11:12-31.
7. Messing B, Crenn P, Beau P, Boutron Ruault MC, Rambaud JC, Matuchansky C. Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology 1999;117:1043-50. (Pubitemid 29512662)
8. Nordgaard I, Hansen BS, Mortensen PB. Importance of colonic support for energy absorption as small- bowel failure proceeds. Am J Clin Nutr 1996;64:222-31. (Pubitemid 26250843)
9. Behrend C, Jeppesen PB, Mortensen PB. Vitamin B12 absorption after ileorectal anastomosis for Crohn's disease: effect of ileal resection and time span after surgery. Eur J Gastroenterol Hepatol 1995;7:397-400.
10. Hofmann AF. Bile acid malabsorption caused by ileal resection. Arch Intern Med 1972;130:597-605.
11. Spiller RC. Feedforward and feedback control mechanisms in the gut. With special emphasis on inhibitory feedback by nutrients in the distal small bowel and colon. Dig Dis 1990;8:189-205.
12. Spiller RC, Trotman IF, Adrian TE et al. Further characterisation of the 'ileal brake' reflex in man- effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY. Gut 1988;29:1042-51.
13. Goulet O, Joly F, Corriol O et al. Some new insights in intestinal failure-associated liver disease. Curr Opin Organ Transplant 2009;14:256-61.
14. Lauverjat M, Hadj AA, Vanhems P et al. Chronic dehydration may impair renal function in patients with chronic intestinal failure on long-term parenteral nutrition. Clin Nutr 2006;25:75-81.
15. Jeppesen PB, Langholz E, Mortensen PB. Quality of life in patients receiving home parenteral nutrition. Gut 1999;44:844-52. (Pubitemid 29244222)
16. Baxter JP, Fayers PM, McKinlay AW. A review of the quality of life of adult patients treated with long-term parenteral nutrition. Clin Nutr 2006;25:543-53. (Pubitemid 44070594)
17. Crenn P, Morin MC, Joly F, Penven S, Thuillier F, Messing B. Net digestive absorption and adaptive hyperphagia in adult short bowel patients. Gut 2004;53:1279-86. (Pubitemid 39120113)
18. Joly F, Dray X, Corcos O, Barbot L, Kapel N, Messing B. Tube feeding improves intestinal absorption in short bowel syndrome patients. Gastroenterology 2009;136:824-31.
19. Nordgaard I, Hansen BS, Mortensen PB. Colon as a digestive organ in patients with short bowel [see comments]. Lancet 1994;343:373-6. (Pubitemid 24049553)
20. Jeppesen PB, Mortensen PB. The influence of a preserved colon on the absorption of medium chain fat in patients with small bowel resection. Gut 1998;43:478-83. (Pubitemid 28462031)
21. Heydorn S, Jeppesen PB, Mortensen PB. Bile acid replacement therapy with cholylsarcosine for short-bowel syndrome. Scand J Gastroenterol 1999;34:818-23. (Pubitemid 29434498)
22. Jeppesen PB, Mortensen PB. Colonic digestion and absorption of energy from carbohydrates and medium-chain fat in small bowel failure. JPEN J Parenter Enteral Nutr 1999;23(5 Suppl).S101-5.
23. Atia A, Girard-Pipau F, Hébuterne X, Spies WG, Guardiola A, Ahn CW et al. Macronutrient absorption characteristics in humans with short bowel syndrome and jejunocolonic anastomosis: starch is the most important carbohydrate substrate, although pectin supplementation may modestly enhance short chain fatty acid production and fluid absorption. JPEN J Parenter Enteral Nutr 2011;35:229-40.
24. van der Hulst RR, van Kreel BK, von Meyenfeldt MF, Brummer RJ, Arends JW, Deutz NE et al. Glutamine and the preservation of gut integrity [see comments]. Lancet 1993;341:1363-5. (Pubitemid 23159983)
25. Beaugerie L, Carbonnel F, Hecketsweiler B, Déchelotte P, Gendre JP, Cosnes J. Effects of an isotonic oral rehydration solution, enriched with glutamine on fluid and sodium absorption in patients with a short-bowel. Alimentary Pharmacology and Therapeutics 1997;11:741-6. (Pubitemid 27376363)
26. Scolapio JS, McGreevy K, Tennyson GS, Burnett OL. Effect of glutamine in short-bowel syndrome. Clin Nutr 2001;20:319-23. (Pubitemid 32785472)
27. Nightingale JM, Lennard Jones JE, Walker ER, Farthing MJ. Oral salt supplements to compensate for jejunostomy losses: comparison of sodium chloride capsules, glucose electrolyte solution, and glucose polymer electrolyte solution. Gut 1992;33:759-61.
28. King RF, Norton T, Hill GL. A double-blind crossover study of the effect of loperamide hydrochloride and codeine phosphate on ileostomy output. Aust N Z J Surg 1982;52:121-4. (Pubitemid 12124660)
29. Newton CR. Effect of codeine phosphate, Lomotil, and Isogel on ileostomy function. Gut 1978;19:377-83. (Pubitemid 8342981)
30. Rovera G, Furukawa H, Reyes J, Todo S, Hutson W. The use of clonidine for the treatment of high intestinal output following small bowel transplantation. Transplant Proc 1997;29:1853-4. (Pubitemid 27203700)
31. Buchman AL, Fryer J, Wallin A, Ahn CW, Polensky S, Zaremba K. Clonidine reduces diarrhea and sodium loss in patients with proximal jejunostomy: a controlled study. JPEN J Parenter Enteral Nutr 2006;30:487-91.
32. Jeppesen PB, Staun M, Tjellesen L, Mortensen PB. Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection. Gut 1998;43:763-9. (Pubitemid 28539654)
33. Ladefoged K, Christensen KC, Hegnhøj J, Jarnum S. Effect of a long acting somatostatin analogue SMS 201-995 on jejunostomy effluents in patients with severe short bowel syndrome [see comments]. Gut 1989;30:943-9. (Pubitemid 19187935)
34. O'Keefe SJ, Haymond MW, Bennet WM, Oswald B, Nelson DK, Shorter RG. Long-acting somatostatin analogue therapy and protein metabolism in patients with jejunostomies. Gastroenterology 1994;107:379-88. (Pubitemid 24233311)
35. O'Keefe SJ, Peterson ME, Fleming CR. Octreotide as an adjunct to home parenteral nutrition in the management of permanent end-jejunostomy syndrome. JPEN J Parenter Enteral Nutr 1994;18:26-34.
36. Sukhotnik I, Khateeb K, Krausz MM, Sabo E, Siplovich L, Coran AG et al. Sandostatin impairs postresection intestinal adaptation in a rat model of short bowel syndrome. Dig Dis Sci 2002;47:2095-102. (Pubitemid 35024828)
37. Seydel AS, Miller JH, Sarac TP, Ryan CK, Chey WY, Sax HC. Octreotide diminishes luminal nutrient transport activity, which is reversed by epidermal growth factor. Am J Surg 1996;172:267-71. (Pubitemid 26327913)
38. Bass BL, Fischer BA, Richardson C, Harmon JW. Somatostatin analogue treatment inhibits post-resectional adaptation of the small bowel in rats. Am J Surg 1991;161:107-11.
39. Staun M, Pironi L, Bozzetti F, Baxter J, Forbes A, Joly F et al. ESPEN Guidelines on Parenteral Nutrition: home parenteral nutrition (HPN) in adult patients. Clin Nutr 2009;28:467-79.
40. Parekh NR, Steiger E. Criteria for the use of recombinant human growth hormone in short bowel syndrome. Nutr Clin Pract 2005;20:503-8. (Pubitemid 350042713)
41. Guarino A, Canani RB, Iafusco M, Casola A, Russo R, Rubino A. In vivo and in vitro effects of human growth hormone on rat intestinal ion transport. Pediatr Res 1995;37:576-80.
42. Byrne TA, Morrissey TB, Nattakom TV, Ziegler TR, Wilmore DW Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with severe short bowel syndrome. JPEN J Parenter Enteral Nutr 1995;19:296-302.
43. Jeppesen PB. The use of hormonal growth factors in the treatment of patients with short-bowel syndrome. Drugs 2006;66:581-9. (Pubitemid 43671452)
44. Ellegard L, Bosaeus I, Nordgren S, Bengtsson BA. Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome. Ann Surg 1997;225:88-96. (Pubitemid 27026807)
45. Scolapio JS, Camilleri M, Fleming CR, Oenning LV, Burton DD, Sebo TJ et al. Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: A randomized, controlled study. Gastroenterology 1997;113:1074-81. (Pubitemid 27418959)
46. Szkudlarek J, Jeppesen PB, Mortensen PB. Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. Gut 2000;47:199-205. (Pubitemid 30489762)
47. Byrne TA, Wilmore DW, Iyer K, Dibaise J, Clancy K, Robinson MK et al. Growth hormone, glutamine, and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, placebo-controlled, double-blind clinical trial. Ann Surg 2005;242:655-61. (Pubitemid 41567120)
48. Seguy D, Vahedi K, Kapel N, Souberbielle JC, Messing B. Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: a positive study. Gastroenterology 2003;124:293-302. (Pubitemid 36169246)
49. Johannsson G, Sverrisdóttir YB, Ellegård L, Lundberg PA, Herlitz H. GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis. J Clin Endocrinol Metab 2002;87:1743-9. (Pubitemid 34618504)
50. Jeppesen PB. Growth factors in short-bowel syndrome patients. Gastroenterol Clin North Am 2007;36:109-21. (Pubitemid 46667221)
51. Liu X, Murali SG, Holst JJ, Ney DM. Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulinlike growth factor-I responses in rats. Am J Physiol Regul Integr Comp Physiol 2008;295.R1794-R1802.
52. Estall JL, Drucker DJ. Glucagon-like Peptide-2. Annu Rev Nutr 2006;26:391-411.
53. Hornby PJ, Moore BA. The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease. Expert Opin Ther Targets 2011;15:637-46.
54. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon- like peptide 2. Proc Natl Acad Sci U S A 1996;93:7911-6. (Pubitemid 26277138)
55. Burrin DG, Stoll B, Guan X, Cui L, Chang X, Holst JJ. Glucagon-like peptide 2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology 2005;146:22-32. (Pubitemid 40051718)
56. Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ. Intestinal growth-promoting properties of glucagon-like peptide- 2 in mice. Am J Physiol 1997;273(1 Pt 1):E77-84.
57. Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol 1998;275(5 Pt 1):G911-21.
58. Koopmann MC, Chen X, Holst JJ, Ney DM. Sustained glucagon-like peptide-2 infusion is required for intestinal adaptation, and cessation reverses increased cellularity in rats with intestinal failure. Am J Physiol Gastrointest Liver Physiol 2010;299:G1222-G1230.
59. Moore BA, Peffer N, Pirone A, Bassiri A, Sague S, Palmer JM et al. GLP-2 receptor agonism ameliorates inflammation and gastrointestinal stasis in murine postoperative ileus. J Pharmacol Exp Ther 2010;333:574-83.
60. Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG; Teduglutide Study Group. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis 2010;16:962-73.
61. Henriksen DB, Alexandersen P, Hartmann Bm, Adrian CL, Byrjalsen I, Bone HG et al. Four-month treatment with GLP-2 significantly increases hip BMD A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009;45:833-42.
62. Thulesen J, Hartmann B, Kissow H, Jeppesen PB, Orskov C, Holst JJ et al. Intestinal growth adaptation and glucagon-like peptide 2 in rats with ileal - jejunal transposition or small bowel resection. Dig Dis Sci 2001;46:379-88. (Pubitemid 32242689)
63. Jeppesen PB, Hartmann B, Hansen BS, Thulesen J, Holst JJ, Mortensen PB. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut 1999;45:559-63. (Pubitemid 29447825)
64. Jeppesen PB, Hartmann B, Thulesen J et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 2000;47(3):370-6.
65. Wojdemann M, Wettergren A, Hartmann B, Hansen BS, Holst JJ, Poulsen SS et al. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998;33.828-32.
66. Wojdemann M, Wettergren A, Hartmann B, Hilsted L, Holst JJ. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 1999;84:2513-7.
67. Jeppesen PB. Clinical significance of GLP-2 in short-bowel syndrome. J Nutr 2003;133:37214.
68. Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001;120:806-15. (Pubitemid 32193176)
69. Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005;54:1224-31. (Pubitemid 41192479)
70. Jeppesen PB, Lund P, Gottschalck IB, Nielsen HB, Holst JJ, Mortensen J et al. Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract 2009;2009:616054.
71. Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 2011;60:902-16.
72. Thulesen J, Hartmann B, Hare KJ, Kissow H, Ørskov C, Holst JJ et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 2004;53:1145-50. (Pubitemid 38961969)
73. Chan S, McCowen KC, Bistrian BR, Thibault A, Keane-Ellison M, Forse RA et al. Incidence, prognosis, and etiology of end-stage liver disease in patients receiving home total parenteral nutrition. Surgery 1999;126:28-34. (Pubitemid 29340688)
74. Garg M, Jones RM, Vaughan RB, Testro AG. Intestinal transplantation: current status and future directions. J Gastroenterol Hepatol 2011;26:1221-8.